XML 108 R51.htm IDEA: XBRL DOCUMENT
v3.25.0.1

List of principal companies included in the scope of consolidation during 2023 | 12 Months Ended
--- | ---
Dec. 31, 2024
Interests In Other Entities [Abstract] |
List of principal companies included in the scope of consolidation during 2023 | F/ List of principal companies included in the scope of consolidation during 2024 F.1. Principal fully consolidated companies The table below shows Sanofi’s principal subsidiaries and their country of incorporation:
Europe |  | Financial interest (%) as of December 31, 2024
Hoechst GmbH * | Germany | 100.0
Sanofi-Aventis Deutschland GmbH | Germany | 100.0
A. Nattermann & Cie GmbH | Germany | 100.0
Sanofi-Aventis GmbH | Austria | 100.0
Sanofi Belgium | Belgium | 100.0
Ablynx NV | Belgium | 100.0
Genzyme Flanders BV | Belgium | 100.0
Sanofi A/S | Denmark | 100.0
Sanofi-Aventis SA | Spain | 100.0
Opella Healthcare Spain, SL | Spain | 100.0
Sanofi Oy | Finland | 100.0
Sanofi | France | 100.0
Sanofi Winthrop Industrie * | France | 100.0
Sanofi-Aventis Recherche & Développement | France | 100.0
Sanofi-Aventis Groupe | France | 100.0
Sanofi-Aventis Participations * | France | 100.0
Sanofi Pasteur | France | 100.0
Aventis Pharma SA | France | 100.0
Aventis Agriculture | France | 100.0
Sanofi Biotechnology * | France | 100.0
Sanofi Pasteur NVL | France | 100.0
Sanofi Pasteur Europe | France | 100.0
Opella Healthcare | France | 100.0
Sanofi Pasteur Merieux SAS | France | 100.0
Opella Healthcare International SAS | France | 100.0
Opella Healthcare France SAS | France | 100.0
Opella Healthcare Group SAS | France | 100.0
Genzyme Polyclonals SAS | France | 100.0
Sanofi-Aventis AEBE | Greece | 100.0
Sanofi-Aventis Private Co Ltd | Hungary | 99.6
Chinoin Private Co Ltd | Hungary | 99.6
Opella Healthcare Hungary Commercial KFT | Hungary | 100.0
Opella Healthcare Hungary KFT | Hungary | 100.0
Carraig Insurance DAC | Ireland | 100.0
Genzyme Ireland Limited | Ireland | 100.0
Sanofi-Aventis Ireland Ltd | Ireland | 100.0
Sanofi-aventis Holdings (Ireland) Ltd | Ireland | 100.0
Sanofi SRL | Italy | 100.0
Opella Healthcare Italy SRL | Italy | 100.0
Genzyme Global Sarl | Luxembourg | 100.0
Genzyme Luxembourg Sarl | Luxembourg | 100.0
Le Rock Re | Luxembourg | 100.0
Sanofi-aventis Norge AS | Norway | 100.0
Sanofi BV * | Netherlands | 100.0
Sanofi Foreign Participations BV * | Netherlands | 100.0
Europe |  | Financial interest (%) as of December 31, 2024
Opella Healthcare Participation BV | Netherlands | 100.0
Sanofi-Aventis Sp zoo | Poland | 100.0
Opella Healthcare Poland sp.ZOO | Poland | 100.0
Sanofi Produtos Farmaceuticos Lda | Portugal | 100.0
Sanofi sro | Czech Republic | 100.0
Sanofi Romania SRL | Romania | 100.0
Opella Healthcare Romania SRL | Romania | 100.0
Sanofi-Aventis UK Holdings Limited | United Kingdom | 100.0
Aventis Pharma Limited | United Kingdom | 100.0
Sanofi-Synthelabo UK Ltd | United Kingdom | 100.0
Aventis Pharma Holdings Ltd | United Kingdom | 100.0
Opella Healthcare UK Limited | United Kingdom | 100.0
AO Sanofi Russia | Russia | 100.0
Opella Healthcare LLC | Russia | 100.0
Sanofi AB | Sweden | 100.0
Sanofi-Aventis (Suisse) SA | Switzerland | 100.0
Genzyme Global Sarl Baar Intellectual Property Branch | Switzerland | 100.0
Sanofi Ilac Sanayi ve Ticaret AS | Turkey | 100.0
Sanofi Pasteur Asi Ticaret AS | Turkey | 100.0
Opella Healthcare Tüketici Sağlığı Anonim Şirketi | Turkey | 100.0
Sanofi Saglik Urunleri Limited Sirketi | Turkey | 100.0
United States |  | Financial interest (%) as of December 31, 2024
Genzyme Therapeutic Products Limited Partnership | United States | 100.0
Aventis Inc * | United States | 100.0
Sanofi US Services Inc | United States | 100.0
Sanofi-Aventis U.S. LLC | United States | 100.0
Chattem, Inc | United States | 100.0
Aventisub LLC | United States | 100.0
Genzyme Corporation * | United States | 100.0
Sanofi Pasteur Inc * | United States | 100.0
VaxServe, Inc | United States | 100.0
Bioverativ Inc | United States | 100.0
Bioverativ U.S.LLC | United States | 100.0
Bioverativ USA Inc | United States | 100.0
Bioverativ Therapeutics Inc | United States | 100.0
Principia Biopharma Inc | United States | 100.0
Sanofi Ventures LLC | United States | 100.0
Sanofi Bioverativ Holdings LLC | United States | 100.0
RPR US Ltd | United States | 100.0
Kadmon Pharmaceuticals LLC | United States | 100.0
Kadmon Corporation, LLC | United States | 100.0
Synthorx, Inc | United States | 100.0
Provention Bio | United States | 100.0
QRIB Intermediate Holding | United States | 100.0
QRI | United States | 100.0
Gold Bond Co LLC | United States | 100.0
Chattem (GB) Holding | United States | 100.0
Sanofi AATD, Inc | United States | 100.0
Translate Bio, Inc | United States | 100.0
Other Countries |  | Financial interest (%) as of December 31, 2024
Sanofi-Aventis South Africa (Pty) Ltd | South Africa | 100.0
Sanofi-Aventis Algérie | Algeria | 100.0
Sanofi Arabia Trading Company Limited | Saudi Arabia | 100.0
Sanofi-Aventis Argentina SA | Argentina | 100.0
Opella Healthcare Argentina SAU | Argentina | 100.0
Genzyme de Argentina SA | Argentina | 100.0
Sanofi-Aventis Healthcare Pty Ltd | Australia | 100.0
Sanofi-Aventis Australia Pty Ltd | Australia | 100.0
Sanofi Medley Farmaceutica Ltda | Brazil | 100.0
Opella Healthcare Brazil Ltda | Brazil | 100.0
Sanofi-Aventis Canada Inc | Canada | 100.0
Sanofi Pasteur Limited | Canada | 100.0
Merieux Canada Holdings ULC (Canada) | Canada | 100.0
Sanofi Vaccines Chile SA | Chile | 100.0
Sanofi (Hangzhou) Pharmaceuticals Co Ltd | China | 100.0
Opella Healthcare Shanghai LTD | China | 100.0
Sanofi (China) Investment Co Ltd | China | 100.0
Sanofi (Beijing) Pharmaceuticals Co Ltd | China | 100.0
Sanofi (Jiangsu) Biologics Co Ltd | China | 100.0
Shenzhen Sanofi pasteur Biological Products Co Ltd | China | 100.0
Shanghai Rongheng Pharmaceutical Co Ltd | China | 100.0
Opella Healthcare Colombia SAS | Colombia | 100.0
Sanofi-Aventis de Colombia SA | Colombia | 100.0
Sanofi-Aventis Korea Co Ltd | South Korea | 100.0
Sanofi-Aventis Gulf FZE | United Arab Emirates | 100.0
Sanofi Egypt | Egypt | 99.8
Sanofi Hong-Kong Limited | Hong Kong | 100.0
Sanofi India Limited | India | 60.4
Sanofi Healthcare India Private Limited | India | 99.9
Sanofi-Aventis Israël Ltd | Israel | 100.0
Sanofi KK | Japan | 100.0
SSP Co Ltd | Japan | 100.0
Sanofi-Aventis (Malaysia) SDN BHD | Malaysia | 100.0
Sanofi-Aventis Maroc | Morocco | 100.0
Sanofi-Aventis de Mexico SA de CV | Mexico | 100.0
Sanofi Pasteur SA de CV | Mexico | 100.0
Azteca Vacunas SA de CV | Mexico | 100.0
Sanofi-Aventis de Panama SA | Panama | 100.0
Opella Healthcare Panama SA | Panama | 100.0
sanofi-aventis Puerto Rico Inc | Puerto Rico | 100.0
Sanofi-Aventis Philippines Inc | Philippines | 100.0
Opella Healthcare Philippines Inc | Philippines | 100.0
Sanofi-Aventis Singapore Pte Ltd * | Singapore | 100.0
Aventis Pharma (Manufacturing) Pte Ltd | Singapore | 100.0
Sanofi Manufacturing Pte Ltd | Singapore | 100.0
Sanofi Taiwan Co Ltd | Taiwan | 100.0
Sanofi-Aventis (Thailand) Ltd | Thailand | 100.0
Sanofi-Aventis de Venezuela SA | Venezuela | 100.0
Sanofi-aventis Vietnam Company Limited | Vietnam | 100.0
Sanofi Vietnam Shareholding Company Limited | Vietnam | 85.0
* Main significant subsidiaries as of December 31, 2024. F.2. Principal investments accounted for using the equity method
|  | Financial interest (%) as of December 31, 2024
Haleon US, LP | United States | 11.7
Infraserv GmbH & Co. Höchst KG | Germany | 31.2
Maphar | Morocco | 48.3
MCM Vaccine BV | Netherlands | 50.0
MSP Vaccine Company (formerly MCM company) | United States | 50.0
EUROAPI | France | 29.6

X
- Definition The disclosure of subsidiaries. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2023-01-01 -Paragraph 17 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2023-01-01 -Paragraph 16 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph B4 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interests In Other Entities [Abstract] + References No definition available. + Details
Name: | sny_InterestsInOtherEntitiesAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration